Literature DB >> 5579860

Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children.

W Marget, D Adam.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5579860     DOI: 10.1111/j.1651-2227.1971.tb06668.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


× No keyword cloud information.
  6 in total

Review 1.  Recent developments in antimycotic chemotherapy.

Authors:  R J Holt
Journal:  Infection       Date:  1974       Impact factor: 3.553

2.  [Treatment of systemic mycosis (author's transl)].

Authors:  T Wegmann
Journal:  Infection       Date:  1973       Impact factor: 3.553

Review 3.  Clotrimazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  P R Sawyer; R N Brogden; R M Pinder; T M Speight
Journal:  Drugs       Date:  1975       Impact factor: 9.546

4.  Laboratory assessment of the antimycotic drug clotrimazole.

Authors:  R J Holt; R L Newman
Journal:  J Clin Pathol       Date:  1972-12       Impact factor: 3.411

5.  Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

Authors:  M A Burgess; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

6.  Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative.

Authors:  S Jevons; G E Gymer; K W Brammer; D A Cox; M R Leeming
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.